Latest Iron News

Litchfield Minerals has identified significant copper mineralisation above key VTEM conductors at its Oonagalabi Project, expanding the known system by over 1km and preparing for a major drilling campaign.

Fenix Resources has locked in exclusive 30-year mining rights over a 290 million tonne iron ore resource at the Weld Range Project, significantly extending its mine life and production capacity. This strategic partnership with Sinosteel Midwest and Baowu Steel Group positions Fenix for ambitious growth in Western Australia's Mid-West.

Bayan Mining and Minerals Limited has reported exceptional early-stage rare earth element assay results from its Desert Star Project in California, with heavy mineral concentrates reaching up to 26,286 ppm TREO. These findings highlight the project's strategic potential near the Mountain Pass Mine, North America's only operating rare earth mine.

Black Canyon Limited has completed Phase 3 drilling at its Wandanya Project, confirming continuous manganese mineralisation along a 3km strike and identifying extensive iron mineralisation nearby.

Cyclone Metals has launched a comprehensive Pre-Feasibility Study for its Iron Bear iron ore project in Canada, aiming to refine development plans and attract global steel market demand.

Genmin Limited has increased insider loans by A$0.5 million, reinforcing funding for its flagship Baniaka iron ore project in Gabon as it targets production in late 2026.

Environmental Clean Technologies Limited reported a $3.52 million net loss for FY2025, marking a modest 5% improvement, while making significant progress in commercialising its COLDry fertiliser technology and securing over $1.7 million in new capital.

Macarthur Minerals Limited reported a successful capital raise and key strategic partnerships at its 2025 AGM, positioning itself for future growth in iron ore production.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

Volt Group Limited reported a 24% revenue decline and a net loss of $271,854 for the half year ended June 2025, primarily due to timing delays in Wescone orders and iron ore sector shutdowns. Despite this, the company advances its innovative ATEN waste heat to power technology and expands its EcoQuip solar light tower fleet, while initiating a 12-month on-market share buy-back.

Orion Equities reported a $1.33 million net profit for FY25, down 56% from the prior year, impacted by unrealised losses on key investments and a significant tax benefit reversal. The company’s portfolio remains anchored by stakes in Bentley Capital and Strike Resources.